Targeting memory T-cells in Type 1 diabetes

Encouraging results from the T1DAL study (Targeting effector memory T cells with alefacept in new onset type 1 diabetes) are published today in The Lancet Diabetes & Endocrinology. The T1DAL trial was designed to test whether alefacept would preserve pancreatic beta cell function in newly diagnosed patients. Secondary endpoints including insulin use and rate of hypoglycemic events were lower at 12 months in the alefacept treated group.

Fuente : http://www.eurekalert.org/pub_releases/2013-09/itn…